Cover Image


View/Hide Left Panel

Merz, D.C., A.Scheid, and P.W.Choppin. 1980. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J. Exp. Med. 151:275–288.

National Institute of Allergy and Infectious Diseases. 1985. Program for Accelerated Development of New Vaccines. Progress Report. Bethesda, Md.: National Institutes of Health.

Parrott, R.H., A.J.Vargosko, H.W.Kim, J.A.Bellanti, and R.M. Chanock. 1962. III. Myxoviruses parainfluenza. Am. J. Public Health 52:907–917.

Portner, A. 1981. The HN glycoprotein of Sendai virus: Analysis of site(s) involved in hemagglutinating and neuraminidase activities. Virology 115:375–384.

Scheid, A., and P.W.Choppin. 1974. Identification of biologicalactivities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai Virus. Virology 57:475–490.

Scheid, A., A.L.Caliguiri, R.W.Compans, and P.W.Choppin. 1972. Isolation of paramyxovirus glycoprotein. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein. Virology 50:640–652.

Smith, C.B., R.H.Purcell, J.A.Bellanti, and R.M.Chanock. 1966. Protective effect of antibody to parainfluenza type 1 virus. N. Engl. J. Med. 275:1145–1152.

Wigley, F.M., M.H.Fruchtman, and R.H.Waldman. 1970. Aerosol immunization of humans with inactivated parainfluenza type 2 vaccine. N. Engl. J. Med. 283:1250–1253.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement